Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport
Molecular Pharmaceutics · 03.03.2025 · 22 (3) · 1555-1567
DOI: 10.1021/acs.molpharmaceut.4c01272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 11.02.2025. Verfasst von Luojuan Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Seaport Therapeutics, 6 Tide Street, Boston, Massachusetts 02210, United States. Hauptthemen laut MEDLINE: Prodrugs, Mycophenolic Acid, Triglycerides, Immunologic Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Health and Medical Research Council, PureTech Health, Australian Research Council.
Abstract (Originalsprache)
Enhanced transport of immunomodulators via the lymphatics may increase drug exposure to therapeutic targets in the immune system. Our laboratory has demonstrated a triglyceride (TG) mimetic prodrug approach to enhance the lymphatic delivery of a model immunomodulator, mycophenolic acid (MPA), via conjugation of the carboxylic acid of MPA to a TG backbone, where the so formed prodrug is able to incorporate into intestinal TG deacylation-reacylation and lymph lipoprotein transport pathways (up to 37% of the administered dose being absorbed via the lymphatics). In the current study, another conjugation site in the molecule of MPA, i.e., the phenolic group, was explored for its potential to optimize the lymphatic transport profiles of TG mimetic prodrugs of MPA. This offers an unusual opportunity to directly compare the utility of TG prodrugs formed via conjugation to an acid versus a phenol in the same core molecule, which has not been examined previously for other parent drugs. A series of linkers were examined to connect the MPA moiety with the TG backbone. Lymphatic transport was assessed in mesenteric lymph duct cannulated rats, and drug exposure in the mesenteric lymph nodes was examined following oral administration to mice. Compared to the data observed previously for MPA prodrugs conjugated via the carboxylic acid, the new phenol-conjugated prodrugs showed clearly different profiles in terms of the linker chemistry. Prodrugs with shorter chain alkyl spacers (e.g., C4 and C6) supported minimal lymphatic transport (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Seaport Therapeutics, 6 Tide Street, Boston, Massachusetts 02210, United States.
ORCID-Profile: Natalie L Trevaskis, Sifei Han, Christopher J H Porter
Förderung
- National Health and Medical Research Council
- PureTech Health
- Australian Research Council
- Seaport Therapeutics
Zitieren
APA
Hu, L., Quach, T., Zheng, D., Leong, N. J., Sharma, G., Lim, S. F., Bonner, D., Trevaskis, N. L., Simpson, J. S., Han, S., & Porter, C. J. H. (2025). Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport. Molecular Pharmaceutics, 22(3), 1555-1567. https://doi.org/10.1021/acs.molpharmaceut.4c01272
Vancouver
Hu L, Quach T, Zheng D, Leong NJ, Sharma G, Lim SF, et al. Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport. Molecular Pharmaceutics. 2025;22(3):1555-1567. doi:10.1021/acs.molpharmaceut.4c01272
BibTeX
@article{Hu2025,
author = {Hu, Luojuan and Quach, Tim and Zheng, Dan and Leong, Nathania J and Sharma, Garima and Lim, Shea Fern and Bonner, Daniel and Trevaskis, Natalie L and Simpson, Jamie S and Han, Sifei and Porter, Christopher J H},
title = {Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {3},
pages = {1555--1567},
doi = {10.1021/acs.molpharmaceut.4c01272}
}
EUVIMED